Project Grant HT94252310069
Award Date
9/30/23
Completion Date
8/31/25
Dollars Obligated
$438K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
This Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $566,810.00 to Brigham & Women's Hospital Inc., a non-profit hospital and research institution in Boston, MA, to support research on the neural regulation of small cell lung cancer progression. The award period is from September 1, 2023 to August 31, 2025. Brigham & Women's Hospital Inc. has previously conducted biomedical research and provided...
The Defense Health Agency awarded a $970,871 Project Grant to Brigham & Women's Hospital Inc. for the project "TARGETING METASTATIC LUNG TUMORS WITH GENE-EDITED AND ENGINEERED STEM CELLS". The grant, funded through the Military Medical Research and Development program (CFDA 12.420), aims to develop innovative treatments for lung cancer and other conditions relevant to military personnel and civilians. Brigham & Women's Hospital, a non-profit healthcare and research institution,...
The federal Project Grant award of $644,400 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support research by Brigham & Women's Hospital Inc. to optimize anti-PD1-based therapy for metastatic renal cell carcinoma. The research aims to transform healthcare for military service members and the general public by advancing innovative approaches to disease prevention, diagnosis, and treatment. The research will be conducted at...
The Department of Defense's Defense Health Agency awarded a $263,598 project grant to Brigham & Women's Hospital Inc. in Boston, MA to conduct research for the "LAM-TARGETING NANOPARTICLE-ASSISTED AND BASE EDITOR-ENABLED GENE THERAPY FOR LYMPHANGIOLEIOMYOMATOSIS" project. This 24-month grant, which runs from August 1, 2024 to July 31, 2026, is funded under the Military Medical Research and Development (CFDA 12.420) program. The project aims to develop novel gene therapy...
The U.S. Defense Health Agency awarded Brigham & Women's Hospital Inc. a $653,343 Project Grant under the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to identify novel therapeutic strategies for chromophobe renal cell carcinoma. The three-year project, with a period of performance from Sep 30, 2023 to Sep 29, 2026, will focus on basic and applied biomedical research to develop innovative treatments for this rare form of kidney cancer. As a...
The Defense Health Agency awarded a $682,266 Project Grant to Brigham & Women's Hospital Inc. under the Military Medical Research and Development program (CFDA 12.420) on May 15, 2024. The grant supports research to develop targeted endothelial cell-derived extracellular vesicle nanoparticles for immunotherapy against brain cancer, with a performance period ending on May 14, 2026. As a subsidiary of Partners Healthcare System Incorporated, Brigham & Women's Hospital has extensive...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $660,937 project grant to Brigham & Women's Hospital Inc. on September 30, 2023, to support the "Identification of Novel Therapeutic Strategies for Chromophobe RCC" research project. This 3-year grant will fund basic and applied biomedical research to investigate new treatment approaches for chromophobe renal cell carcinoma, a rare form of kidney cancer. Brigham & Women's...
Brigham & Women's Hospital Inc. was awarded a $1,523,784 Project Grant from the Department of the Army Medical Command's Military Medical Research and Development program to investigate cytoplasmic DNA-sensing pathways in BRCA1-deficient breast cancer development. The three-year award beginning July 1, 2022 will support research into medical solutions for breast cancer at the cellular level through studying the role of cytoplasmic DNA sensors in breast cancer tumor growth associated with...
The Defense Health Agency has awarded a $1,683,194 Project Grant to Brigham & Women's Hospital Inc. under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, effective from August 1, 2025 to July 31, 2028, will fund research focused on the role of the glycome in TSC biomarker identification and molecular pathogenesis. Brigham & Women's Hospital Inc., a prominent academic medical center and research institution affiliated with Harvard Medical...
The Defense Health Agency awarded a $1,318,799.00 Project Grant to Brigham & Women's Hospital Inc. in Boston, MA on June 15, 2023 under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "THE BRIDGE PROJECT: BROADENING THE REACH OF IMAGING, DIAGNOSTICS, AND GENETIC EVALUATION", will fund research and development to transform healthcare for U.S. military service members and the public through innovative medical solutions for the battlefield and...